{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-007001","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.211081+00:00","generated_at":"2026-06-18T08:51:38.188743+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biofrontera reports Q4 2022 rev $10.1M (+11% YoY); FY rev $28.7M (+19%); guides 25% growth in 2023","bullets":["Total revenue Q4 2022 $10.1M (+11% YoY); FY 2022 $28.7M (+19% YoY).","Net loss Q4 $2.8M vs $14.5M in Q4 2021; FY net loss $0.64M vs $37.7M in 2021.","Adjusted EBITDA negative $4.4M in Q4 and negative $18.1M for FY 2022.","Guidance: FY 2023 revenue growth at least 25%; expects cash flow positive within ~2 years.","Expanding salesforce to 50-55 over next couple of years; will stop providing preliminary quarterly revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-007001","json":"https://secwatch.observer/filing/0001493152-23-007001.json","markdown":"https://secwatch.observer/filing/0001493152-23-007001.md","text":"https://secwatch.observer/filing/0001493152-23-007001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223007001/0001493152-23-007001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223007001/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:51:38.188743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7398d5f6b23d7a77d283f99879b0f39444469d9e","claim":"Biofrontera Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $10.1 million, net income $2.8 million. Guidance raised.","evidence_excerpt":"at least 25% over last year positioning us well to be cashflow positive within approximately two years.” Fourth Quarter Financial Results Fourth quarter 2022 total revenues of $10.1 million, compared with $9.2 million in the fourth quarter of 2021. The increase was driven by continued growth in the sales of Ameluz, partially offset by shipping delays and some sales","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223007001/0001493152-23-007001-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$10.1 million"},{"label":"Net income","value":"$2.8 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}